Eli Lilly and Co. (NYSE:LLY) announced a quarterly dividend on Monday, October 17th. Shareholders of record on Tuesday, November 15th will be given a dividend of 0.51 per share on Friday, December 9th. This represents a $2.04 annualized dividend and a dividend yield of 2.57%.

Shares of Eli Lilly and (NYSE:LLY) traded down 0.96% on Monday, hitting $78.51. The stock had a trading volume of 2,250,085 shares. The stock has a market cap of $83.04 billion, a PE ratio of 33.84 and a beta of 0.17. The company has a 50 day moving average price of $79.73 and a 200-day moving average price of $77.79. Eli Lilly and has a 12 month low of $67.88 and a 12 month high of $88.16.

Eli Lilly and (NYSE:LLY) last released its quarterly earnings data on Tuesday, July 26th. The company reported $0.86 earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of $0.86. Eli Lilly and had a net margin of 11.97% and a return on equity of 23.99%. The firm had revenue of $5.40 billion for the quarter, compared to the consensus estimate of $5.14 billion. During the same period last year, the firm earned $0.90 earnings per share. The company’s quarterly revenue was up 8.6% on a year-over-year basis. On average, equities research analysts anticipate that Eli Lilly and will post $3.59 earnings per share for the current year.

Dividend History for Eli Lilly and (NYSE:LLY)

LLY has been the subject of a number of research analyst reports. Argus raised their price target on shares of Eli Lilly and from $90.00 to $95.00 and gave the company a “buy” rating in a research report on Tuesday, August 2nd. Zacks Investment Research upgraded shares of Eli Lilly and from a “hold” rating to a “buy” rating and set a $92.00 price target on the stock in a research report on Friday, August 5th. Leerink Swann restated a “buy” rating on shares of Eli Lilly and in a research report on Sunday, June 26th. BMO Capital Markets restated an “outperform” rating and set a $94.00 price target on shares of Eli Lilly and in a research report on Tuesday, September 27th. Finally, Goldman Sachs Group Inc. upgraded shares of Eli Lilly and from a “neutral” rating to a “buy” rating and raised their price target for the company from $89.00 to $95.00 in a research report on Tuesday, September 27th. Three research analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $97.06.

In related news, Director Jackson P. Tai bought 2,560 shares of the stock in a transaction dated Friday, August 12th. The stock was acquired at an average price of $80.42 per share, for a total transaction of $205,875.20. Following the acquisition, the director now owns 42,110 shares in the company, valued at approximately $3,386,486.20. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Maria A. Crowe sold 2,248 shares of the company’s stock in a transaction on Wednesday, October 5th. The shares were sold at an average price of $81.37, for a total transaction of $182,919.76. Following the completion of the transaction, the insider now owns 94,319 shares of the company’s stock, valued at approximately $7,674,737.03. The disclosure for this sale can be found here. Company insiders own 0.20% of the company’s stock.

A number of hedge funds have recently added to or reduced their stakes in the stock. Franklin Resources Inc. increased its position in shares of Eli Lilly and by 2.5% in the second quarter. Franklin Resources Inc. now owns 28,430,876 shares of the company’s stock worth $2,238,939,000 after buying an additional 685,898 shares during the last quarter. Massachusetts Financial Services Co. MA increased its position in shares of Eli Lilly and by 6.4% in the second quarter. Massachusetts Financial Services Co. MA now owns 11,913,007 shares of the company’s stock worth $938,150,000 after buying an additional 715,620 shares in the last quarter. Janus Capital Management LLC increased its position in shares of Eli Lilly and by 15.9% in the second quarter. Janus Capital Management LLC now owns 10,021,381 shares of the company’s stock worth $789,162,000 after buying an additional 1,377,814 shares in the last quarter. Capital World Investors increased its position in shares of Eli Lilly and by 6.3% in the second quarter. Capital World Investors now owns 6,314,000 shares of the company’s stock worth $497,228,000 after buying an additional 373,000 shares in the last quarter. Finally, APG Asset Management N.V. increased its position in shares of Eli Lilly and by 5.6% in the second quarter. APG Asset Management N.V. now owns 4,527,642 shares of the company’s stock worth $356,552,000 after buying an additional 239,179 shares in the last quarter. Hedge funds and other institutional investors own 74.99% of the company’s stock.

About Eli Lilly and

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

5 Day Chart for NYSE:LLY

Receive News & Stock Ratings for Eli Lilly and Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Co. and related stocks with our FREE daily email newsletter.